ABVC BioPharma, Inc. (ABVC) shareholders
Close on Nov 16, 2026Market cap $25.06MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lind Global Fund II LP Joint filing with Lind Global Partners II LLC (9.90%), Easton Jeff (9.90%) | 1,325,000 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Eugene Jiang | 131,159 | 18.50% | 13D (active) amendment | Jul 10, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABVC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 374,499 | – | $591.71K | +183,925 | 0.00% |
| Geode Capital Management, LLC | 228,042 | – | $360.38K | +6,873 | 0.00% |
| Vanguard Fiduciary Trust Co | 97,363 | – | $153.83K | – | 0.00% |
| State Street Corp | 72,800 | – | $115.02K | – | 0.00% |
| Citadel Advisors LLC | 72,091 | – | $113.90K | New | 0.00% |
| BlackRock, Inc. | 56,442 | – | $89.18K | – | 0.00% |
| Northern Trust Corp | 48,643 | – | $76.86K | +16,556 | 0.00% |
| XTX Topco Ltd | 48,276 | – | $76.28K | New | 0.00% |
| Panagora Asset Management Inc | 36,682 | – | $57.96K | New | 0.00% |
| UBS Group AG | 34,123 | – | $53.91K | +32,352 | 0.00% |
| Jane Street Group, LLC | 20,059 | – | $31.69K | New | 0.00% |
| Citigroup Inc | 540 | – | $853 | New | 0.00% |
| LifeSteps Financial, Inc. | 300 | – | $474 | New | 0.00% |
| Royal Bank of Canada | 17 | – | $0 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 6 | – | $9 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 1M | 7 / 4 | 0 / 5 | 0M | 0M |
| Q1 2026 | 13 | 1M | 6 / 2 | 2 / 6 | 0M | 0M |
| Q4 2025 | 14 | 1M | 2 / 8 | 2 / 2 | 0M | 0M |
| Q3 2025 | 14 | 1M | 6 / 6 | 2 / 1 | 0M | 0M |
| Q2 2025 | 9 | 0M | 1 / 5 | 2 / 2 | 0M | 0M |
| Q1 2025 | 10 | 0M | 0 / 5 | 2 / 3 | 0M | 0M |
| Q4 2024 | 13 | 0M | 4 / 5 | 1 / 0 | 0M | 0M |
| Q3 2024 | 9 | 0M | 1 / 2 | 2 / 2 | 0M | 0M |
| Q2 2024 | 11 | 0M | 5 / 2 | 1 / 2 | 0M | 0M |
| Q1 2024 | 8 | 0M | 2 / 4 | 0 / 2 | 0M | 0M |
| Q4 2023 | 8 | 0M | 1 / 3 | 1 / 2 | 0M | 0M |
| Q3 2023 | 9 | 0M | 9 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held ABVC in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ABVC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 208,279 | – | $329.08K | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 115,243 | – | $182.08K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 109,835 | – | $154.87K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 31,053 | – | $43.78K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 28,657 | – | $40.41K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,128 | – | $8.64K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -100 | – | -$158 | -0.00% | Jun 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kevin Patrick Stolz VP & Controller | Jan 27, 2012 | Award | +6,250 | – | – | 6,250 |
| Joseph Nirta Director | May 11, 2010 | Buy | +10,000 | $0.15 | $1.50K | 10,000 |
| Joseph Nirta Director | Mar 22, 2010 | Buy | +2,000 | $0.26 | $520 | 2,000 |
| J.B. Smith Director, 10% owner | Nov 13, 2009 | Buy | +714,286 | $50000.00 | $35.71B | 16,585,538 |
| Daniel V. Iannotti VP, General Counsel & Secretar | Sep 21, 2009 | Award | +70,000 | $0.51 | $35.70K | 400,000 |
| Frank Thomas Krotine President & COO | Sep 21, 2009 | Award | +169,000 | $0.51 | $86.19K | 510,217 |
| Robert G. Crockett Chief Executive Officer | Sep 21, 2009 | Award | +670,000 | $0.51 | $341.70K | 1,000,000 |
| J.B. Smith Director, 10% owner | Aug 31, 2009 | Buy | +192,308 | $50000.00 | $9.62B | 18,430,752 |
| J.B. Smith Director, 10% owner | Aug 31, 2009 | Buy | +192,308 | $50000.00 | $9.62B | 17,349,752 |
| J.B. Smith Director, 10% owner | Aug 19, 2009 | Gift | −300,000 | – | – | 17,575,000 |
| J.B. Smith Director, 10% owner | Jun 10, 2009 | Buy | +20 | $20000.00 | $400.00K | 336 |
| J.B. Smith Director, 10% owner | Jun 2, 2009 | Buy | +55 | $55000.00 | $3.03M | 2,436 |
| J.B. Smith Director, 10% owner | Jun 2, 2009 | Buy | +40 | $40000.00 | $1.60M | 316 |
| J.B. Smith Director, 10% owner | Apr 29, 2009 | Buy | +34 | $34000.00 | $1.16M | 2,381 |
| J.B. Smith Director, 10% owner | Apr 14, 2009 | Buy | +21 | $21000.00 | $441.00K | 2,347 |
| J.B. Smith Director, 10% owner | Mar 26, 2009 | Buy | +80 | $80000.00 | $6.40M | 2,326 |
| Sally Judith Ramsey Director, 10% owner | Mar 26, 2009 | Buy | +80 | $80000.00 | $6.40M | 2,326 |
| J.B. Smith Director, 10% owner | Mar 10, 2009 | Buy | +23 | $23000.00 | $529.00K | 2,246 |
| J.B. Smith Director, 10% owner | Feb 26, 2009 | Buy | +40 | $40000.00 | $1.60M | 2,223 |
| J.B. Smith Director, 10% owner | Feb 11, 2009 | Buy | +30 | $30000.00 | $900.00K | 2,158 |
| J.B. Smith Director, 10% owner | Feb 10, 2009 | Other | +24 | – | – | 2,128 |
| Richard Dean Stromback Director, 10% owner | Jan 23, 2009 | Sale | −4,000,000 | $1.00 | $4.00M | 10,637,500 |
| J.B. Smith Director, 10% owner | Jan 23, 2009 | Buy | +4,000,000 | – | – | 5,500,000 |
| Richard Dean Stromback Director, 10% owner | Jan 23, 2009 | Sale | −4,000,000 | $1.00 | $4.00M | 10,637,500 |
| J.B. Smith Director, 10% owner | Jan 23, 2009 | Buy | +4,000,000 | $1.00 | $4.00M | 5,500,000 |
| J.B. Smith Director | Sep 26, 2008 | Buy | +750 | $1000.00 | $750.00K | 2,010 |
| Richard Dean Stromback CEO, Director, 10% owner | Aug 18, 2008 | Sale | −1,500,000 | – | – | 14,637,500 |
| Sally Judith Ramsey VP New Product Development | Jul 30, 2007 | Buy | +3,000,000 | – | – | 3,000,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ABVC BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,136 shares on Sep 3, 2026 over the last 90 days.
See a number that looks wrong?